|Bid||37.49 x 1400|
|Ask||38.00 x 1100|
|Day's Range||37.00 - 37.53|
|52 Week Range||25.04 - 43.16|
|Beta (5Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors in QIAGEN N.V. (NYSE:QGEN) had a good week, as its shares rose 5.8% to close at US$35.75 following the...
Qiagen (QGEN) delivered earnings and revenue surprises of 9.09% and 1.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Benzinga's PreMarket Prep show resumed Thursday after a pause for the Christmas holiday. As always, there were a few market movers to cover and two informative interviews. Qiagen Decides Not To Sell When ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied ...
Qiagen NV shares plummeted more than 25% in late trading on Tuesday after the company announced that a strategic review had ended with a decision to not break up nor sell the business. Qiagen announced last month that it had received "several" entreaties to acquire the molecular-diagnostics specialist, and were exploring the opportunities. Shares, which had been hit hard by a CEO departure and China-related concerns, rebounded on that news. After the shortened Christmas Eve trading session ended, though, Qiagen announced that its management and supervisory boards had opted against a sale and terminated all discussions because "the alternatives to the stand-alone business plan prospects were not compelling." Shares closed Tuesday with a 0.8% increase at $41.47, then dove to less than $31 in after-hours trading following the announcement.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, ...
QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...
QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.
Qiagen NV shares jumped to their highest in almost 19 years on Monday after the German genetic testing company said it would start talks with several potential suitors. The shares had gained 14% on Wednesday, after a report that life sciences tools maker Thermo Fisher Scientific Inc had approached Qiagen about a potential deal. "The Supervisory Board and the Management Board ... are starting discussions with interested parties," the company said on Friday.